drugset / Trial / NCT00215995
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
Phase 2
Completed
21 enrolled
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is for patients with esophageal, esophagogastric, or gastric cancer that has spread to other parts of the body. The purpose of this study is to test the safety and effectiveness of a new experimental drug called ZD 1839 following initial therapy with two other chemotherapy drugs, called Irinotecan (CPT-11) and Cisplatin.
Timeline
- Start
- 2003-07
- Primary completion
- 2007-05
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Gefitinib | Small molecule | — | Oral |
| Subject | Irinotecan | Small molecule | — | — |